Patents by Inventor Cagan Gurer

Cagan Gurer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Genetically modified non-human animals and methods of use thereof
    Patent number: 10561126
    Abstract: Genetically modified non-human animals expressing human SIRP? and human IL-15 from the non-human animal genome are provided. Also provided are methods for making non-human animals expressing human SIRP? and human IL-15 from the non-human animal genome, and methods for using non-human animals expressing human SIRP? and human IL-15 from the non-human animal genome. These animals and methods find many uses in the art, including, for example, in modeling human T cell and/or natural killer (NK) cell development and function, in modeling human pathogen infection of human T cells and/or NK cells, and in various in vivo screens.
    Type: Grant
    Filed: April 16, 2018
    Date of Patent: February 18, 2020
    Assignees: Regeneron Pharmaceuticals, Inc., Yale University, Institute for Research in Biomedicine (IRB)
    Inventors: Dietmar Herndler-Brandstetter, Richard A. Flavell, Davor Frleta, Cagan Gurer, Markus Gabriel Manz, Andrew J. Murphy, Noah W. Palm, Liang Shan, Sean Stevens, Till Strowig, George D. Yancopoulos, Marcel de Zoete
  • Humanized IL-15 animals
    Patent number: 10561125
    Abstract: Genetically modified non-human animals comprising a humanized interleukin-15 (IL-15) gene. Cells, embryos, and non-human animals comprising a human IL-15 gene. Rodents that express humanized or human IL-15 protein.
    Type: Grant
    Filed: December 6, 2017
    Date of Patent: February 18, 2020
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventors: Jose F. Rojas, Ka-Man Venus Lai, Andrew J. Murphy, Cagan Gurer
  • Non-human animals having humanized Fc-gamma receptors
    Patent number: 10555507
    Abstract: Genetically modified mice and methods and compositions for making and using the same are provided, wherein the genetic modification comprises humanization of an Fc?RI protein.
    Type: Grant
    Filed: September 27, 2016
    Date of Patent: February 11, 2020
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Andrew J. Murphy, Lynn Macdonald, Cagan Gurer, Karolina A. Meagher, Naxin Tu
  • Humanized Fc?R mice
    Patent number: 10426848
    Abstract: Genetically modified non-human animals and methods and compositions for making and using them are provided, wherein the genetic modification comprises a deletion of the endogenous low affinity Fc?R locus, and wherein the mouse is capable of expressing a functional FcR?-chain. Genetically modified mice are described, including mice that express low affinity human Fc?R genes from the endogenous Fc?R locus, and wherein the mice comprise a functional FcR?-chain. Genetically modified mice that express up to five low affinity human Fc?R genes on accessory cells of the host immune system are provided.
    Type: Grant
    Filed: May 22, 2017
    Date of Patent: October 1, 2019
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Lynn MacDonald, Naxin Tu, Cagan Gurer, Sean Stevens, Andrew J. Murphy
  • Non-human animals having a humanized signal-regulatory protein gene
    Patent number: 10426146
    Abstract: Genetically modified non-human animals and methods and compositions for making and using the same are provided, wherein the genetic modification comprises a humanization of an endogenous signal-regulatory protein gene, in particular a humanization of a SIRP? gene. Genetically modified mice are described, including mice that express a human or humanized SIRP? protein from an endogenous SIRP? locus.
    Type: Grant
    Filed: January 3, 2019
    Date of Patent: October 1, 2019
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventors: Andrew J. Murphy, O. Gavin Thurston, Bindu Varghese, Cagan Gurer
  • GENETICALLY MODIFIED MAJOR HISTOCOMPATIBILITY COMPLEX MICE
    Publication number: 20190239497
    Abstract: The invention provides genetically modified non-human animals that express a humanized MHC II protein (humanized MHC II ? and ? polypeptides), as well as embryos, cells, and tissues comprising the same. Also provided are constructs for making said genetically modified animals and methods of making the same. Methods of using the genetically modified animals to study various aspects of human immune system are provided.
    Type: Application
    Filed: January 10, 2019
    Publication date: August 8, 2019
    Inventors: Lynn Macdonald, Andrew J. Murphy, Naxin Tu, Cagan Gurer, Vera Voronina, Sean Stevens
  • GENETICALLY MODIFIED MAJOR HISTOCOMPATIBILITY COMPLEX MICE
    Publication number: 20190239496
    Abstract: The invention provides genetically modified non-human animals that express a humanized MHC II protein (humanized MHC II ? and ? polypeptides), as well as embryos, cells, and tissues comprising the same. Also provided are constructs for making said genetically modified animals and methods of making the same. Methods of using the genetically modified animals to study various aspects of human immune system are provided.
    Type: Application
    Filed: January 10, 2019
    Publication date: August 8, 2019
    Inventors: Lynn Macdonald, Andrew J. Murphy, Naxin Tu, Cagan Gurer, Vera Voronina, Sean Stevens
  • HUMAN LAMBDA LIGHT CHAIN MICE
    Publication number: 20190203171
    Abstract: Genetically modified mice are provided that express human ? variable (hV?) sequences, including mice that express hV? sequences from an endogenous mouse ? light chain locus, mice that express hV? sequences from an endogenous mouse ? light chain locus, and mice that express hV? sequences from a transgene or an episome wherein the hV? sequence is linked to a mouse constant sequence. Mice are provided that are a source of somatically mutated human ? variable sequences useful for making antigen-binding proteins. Compositions and methods for making antigen-binding proteins that comprise human ? variable sequences, including human antibodies, are provided.
    Type: Application
    Filed: March 11, 2019
    Publication date: July 4, 2019
    Inventors: Lynn Macdonald, Sean Stevens, Cagan Gurer, Andrew J. Murphy, Karolina A. Meagher
  • Genetically modified major histocompatibility complex mice
    Patent number: 10314296
    Abstract: The invention provides genetically modified non-human animals that express chimeric human/non-human MHC I and MHC II polypeptides and/or human or humanized ?2 microglobulin polypeptide, as well as embryos, cells, and tissues comprising the same. Also provided are constructs for making said genetically modified animals and methods of making the same. Methods of using the genetically modified animals to study various aspects of human immune system are provided.
    Type: Grant
    Filed: December 12, 2017
    Date of Patent: June 11, 2019
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Vera Voronina, Cagan Gurer, Andrew J. Murphy, Lynn Macdonald, Yingzi Xue
  • HUMAN LAMBDA LIGHT CHAIN MICE
    Publication number: 20190153384
    Abstract: Genetically modified mice are provided that express human ? variable (hV?) sequences, including mice that express hV? sequences from an endogenous mouse ? light chain locus, mice that express hV? sequences from an endogenous mouse ? light chain locus, and mice that express hV?, sequences from a transgene or an episome wherein the hV? sequence is linked to a mouse constant sequence. Mice are provided that are a source of somatically mutated human ? variable sequences useful for making antigen-binding proteins. Compositions and methods for making antigen-binding proteins that comprise human ? variable sequences, including human antibodies, are provided.
    Type: Application
    Filed: February 6, 2019
    Publication date: May 23, 2019
    Inventors: Lynn Macdonald, Sean Stevens, Cagan Gurer, Andrew J. Murphy, Karolina A. Meagher
  • GENETICALLY MODIFIED MAJOR HISTOCOMPATIBILITY COMPLEX MICE
    Publication number: 20190133095
    Abstract: The invention provides genetically modified non-human animals that express chimeric human/non-human MHC I and MHC II polypeptides and/or human or humanized ?2 microglobulin polypeptide, as well as embryos, cells, and tissues comprising the same. Also provided are constructs for making said genetically modified animals and methods of making the same. Methods of using the genetically modified animals to study various aspects of human immune system are provided.
    Type: Application
    Filed: November 8, 2018
    Publication date: May 9, 2019
    Inventors: Lynn Macdonald, Andrew J. Murphy, Vera Voronina, Cagan Gurer
  • NON-HUMAN ANIMALS HAVING A HUMANIZED SIGNAL-REGULATORY PROTEIN GENE
    Publication number: 20190124895
    Abstract: Genetically modified non-human animals and methods and compositions for making and using the same are provided, wherein the genetic modification comprises a humanization of an endogenous signal-regulatory protein gene, in particular a humanization of a SIRP? gene. Genetically modified mice are described, including mice that express a human or humanized SIRP? protein from an endogenous SIRP? locus.
    Type: Application
    Filed: January 3, 2019
    Publication date: May 2, 2019
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: Andrew J. Murphy, O. Gavin Thurston, Bindu Varghese, Cagan Gurer
  • NON-HUMAN ANIMALS HAVING A HUMANIZED B-CELL ACTIVATING FACTOR GENE
    Publication number: 20190124897
    Abstract: Non-human animals, cells, methods and compositions for making and using the same are provided, wherein the non-human animals and cells comprise a humanized B-cell activating factor gene. Non-human animals and cells that express a human or humanized B-cell activating factor protein from an endogenous B-cell activating factor locus are described.
    Type: Application
    Filed: January 8, 2019
    Publication date: May 2, 2019
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: John McWhirter, Cagan Gurer, Lynn Macdonald, Andrew J. Murphy
  • Human lambda light chain mice
    Patent number: 10266803
    Abstract: Genetically modified mice are provided that express human ? variable (hV?) sequences, including mice that express hV? sequences from an endogenous mouse ? light chain locus, mice that express hV? sequences from an endogenous mouse ? light chain locus, and mice that express hV? sequences from a transgene or an episome wherein the hV? sequence is linked to a mouse constant sequence. Mice are provided that are a source of somatically mutated human ? variable sequences useful for making antigen-binding proteins. Compositions and methods for making antigen-binding proteins that comprise human ? variable sequences, including human antibodies, are provided.
    Type: Grant
    Filed: November 13, 2017
    Date of Patent: April 23, 2019
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Lynn Macdonald, Sean Stevens, Cagan Gurer, Andrew J. Murphy, Karolina A. Meagher
  • Restricted immunoglobulin heavy chain mice
    Patent number: 10246509
    Abstract: Mice having a restricted immunoglobulin heavy chain locus are provided, wherein the locus is characterized by a single polymorphic human VH gene segment, a plurality of human DH gene segments and a plurality of JH gene segments. Methods for making antibody sequences that bind an antigen (e.g., a viral antigen) are provided, comprising immunizing a mouse with an antigen of interest, wherein the mouse comprises a single human VH gene segment, a plurality of human DH gene segments and a plurality of JH gene segments, at the endogenous immunoglobulin heavy chain locus.
    Type: Grant
    Filed: October 17, 2012
    Date of Patent: April 2, 2019
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Lynn Macdonald, John McWhirter, Cagan Gurer, Karolina A. Hosiawa, Andrew J. Murphy
  • Genetically modified major histocompatibility complex mice
    Patent number: 10219493
    Abstract: The invention provides genetically modified non-human animals that express a humanized MHC II protein (humanized MHC II ? and ? polypeptides), as well as embryos, cells, and tissues comprising the humanized MHC II protein. Also provided are constructs for and methods of making said genetically modified non-human animals. Methods of using the genetically modified non-human animals to study various aspects of the human immune system are provided.
    Type: Grant
    Filed: January 24, 2017
    Date of Patent: March 5, 2019
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Lynn Macdonald, Andrew J. Murphy, Naxin Tu, Cagan Gurer, Vera Voronina, Sean Stevens
  • Non-human animals having a humanized B-cell activating factor gene
    Patent number: 10219494
    Abstract: Non-human animals, cells, methods and compositions for making and using the same are provided, wherein the non-human animals and cells comprise a humanized B-cell activating factor gene. Non-human animals and cells that express a human or humanized B-cell activating factor protein from an endogenous B-cell activating factor locus are described.
    Type: Grant
    Filed: March 15, 2017
    Date of Patent: March 5, 2019
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventors: John McWhirter, Cagan Gurer, Lynn Macdonald, Andrew J. Murphy
  • Non-human animals having a humanized signal-regulatory protein gene
    Patent number: 10206379
    Abstract: Genetically modified non-human animals and methods and compositions for making and using the same are provided, wherein the genetic modification comprises a humanization of an endogenous signal-regulatory protein gene, in particular a humanization of a SIRP? gene. Genetically modified mice are described, including mice that express a human or humanized SIRP? protein from an endogenous SIRP? locus.
    Type: Grant
    Filed: January 10, 2018
    Date of Patent: February 19, 2019
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventors: Andrew J. Murphy, O. Gavin Thurston, Bindu Varghese, Cagan Gurer
  • Genetically modified major histocompatibility complex mice
    Patent number: 10154658
    Abstract: The invention provides genetically modified non-human animals that express chimeric human/non-human MHC I and MHC II polypeptides and/or human or humanized ?2 microglobulin polypeptide, as well as embryos, cells, and tissues comprising the same. Also provided are constructs for making said genetically modified animals and methods of making the same. Methods of using the genetically modified animals to study various aspects of human immune system are provided.
    Type: Grant
    Filed: February 20, 2014
    Date of Patent: December 18, 2018
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Lynn MacDonald, Andrew J. Murphy, Vera Voronina, Cagan Gurer
  • Genetically modified non-human animals and methods of use thereof
    Patent number: 10123518
    Abstract: Genetically modified non-human animals expressing human SIRP? and human IL-15 from the non-human animal genome are provided. Also provided are methods for making non-human animals expressing human SIRP? and human IL-15 from the non-human animal genome, and methods for using non-human animals expressing human SIRP? and human IL-15 from the non-human animal genome. These animals and methods find many uses in the art, including, for example, in modeling human T cell and/or natural killer (NK) cell development and function, in modeling human pathogen infection of human T cells and/or NK cells, and in various in vivo screens.
    Type: Grant
    Filed: April 12, 2016
    Date of Patent: November 13, 2018
    Assignees: Regeneron Pharmaceuticals, Inc, Yale University, Institute For Research In Biomedicine (IRB)
    Inventors: Dietmar Herndler-Brandstetter, Richard A. Flavell, Davor Frleta, Cagan Gurer, Markus Gabriel Manz, Andrew J. Murphy, Noah W. Palm, Liang Shan, Sean Stevens, Till Strowig, George D. Yancopoulos, Marcel de Zoete